Gierschek, FenjaFenjaGierschekSchlueter, JulianeJulianeSchlueterKühnel, InesInesKühnelFeigl, Frederik FabianFrederik FabianFeiglSchmiedel, DominikDominikSchmiedelPrüfer, MarenMarenPrüferBuchinger, LeonLeonBuchingerCerwenka, AdelheidAdelheidCerwenkaCappel, ClaudiaClaudiaCappelHuenecke, SabineSabineHueneckeKöhl, UlrikeUlrikeKöhlWels, Winfried S.Winfried S.WelsUllrich, EvelynEvelynUllrich2024-10-182024-10-182025https://publica.fraunhofer.de/handle/publica/47709310.1159/000540962Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve outcomes for patients with AML. Summary: Recent preclinical studies and early-stage clinical trials aim to enhance the intrinsic anti-leukemic properties of NK cells by selectively targeting AML cells with chimeric antigen receptors (CARs). Furthermore, NK and CAR-NK cells can be combined with other therapeutic modalities or engineered further to overcome the immunosuppressive microenvironment, and treatment resistance of AML blasts and leukemia-initiating cells (LIC). Key Messages: In this review, we summarize preclinical studies with cytokine-stimulated or genetically engineered NK cells derived from different cell sources for the treatment of AML and their translation into early-phase clinical trials. We also provide an overview of promising recent developments toward innovative NK cell-based therapies that may be implemented in the near future.enHematologyOncologyjournal article